Hi, my name is Guraksh Kaur. I'm an assistant professor at UT Southwestern Medical Center in Dallas, Texas. I'm attending ASH 22 and I'm very excited to hear from many folks who are presenting interesting research, specifically in the area post-BCMA. What can we do when people have progressed on a BCMA-specific therapy? And within that, what kind of BCMA-specific therapy, whether it's CAR-T, a bispecific, or an ADC such as Belomov? There was some interesting data presented here that patients who have received BCMA-specific therapy can respond to another BCMA-specific, bispecific antibody like Arlandtamab. There were some interesting responses noted there. Beyond BCMA, there was data in the GPCR5D space. That's very, from Majestic 1, the data is very, very promising. The overall response rates as well as complete responses in a patient population that's very refractory, I think, gives a lot of hope to multiple myeloma patients. So I think as the myeloma community embraces BCMA targets, we're getting ready to know what's coming in the future. What do we expect? What are our new targets? And how are we going to select patients for that?
HealthTree • December 11, 2022